Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome".
MetadataShow full item record
Version of record
Melanoma and Kidney Cancer
License start date
Cancer immunology, immunotherapy : CII, 2016, 65 (6), pp. 769 - 770